Yanhong Deng
Statistician 3DownloadHi-Res Photo
Cards
Additional Titles
Senior Biostatistician
Co-Director of Analytics, Yale Center for Analytical Sciences
Contact Info
About
Copy Link
Titles
Statistician 3
Senior Biostatistician; Co-Director of Analytics, Yale Center for Analytical Sciences
Departments & Organizations
Research
Copy Link
Research Projects
Understanding the Impact of COVID-19 on Individuals with HIV with Tobacco Use: A Mixed-Methods Study
General Internal Medicine / , parent organization of Phoenix LabA SMART Approach to Treating Tobacco Use Disorder in Persons Living with HIV (SMARTTT)
General Internal Medicine / , parent organization of Phoenix Lab
ORCID
0000-0001-6873-8026
Research at a Glance
Yale Co-Authors
Frequent collaborators of Yanhong Deng's published research.
Publications Timeline
A big-picture view of Yanhong Deng's research output by year.
Tianshu Liu
Geliang Gan, MPH, PhD
James Dziura, MPH, PhD
Stephen Parziale, MSc
E. Jennifer Edelman, MD, MHS, AAHIVS
Gary Désir, MD
203Publications
6,005Citations
Publications
2026
Who Gets Panretinal Photocoagulation? National Patterns in Proliferative Diabetic Retinopathy Treatment
Applebaum SS, Fu J, Bakhoum M, Deng Y, Nwanyanwu KH. Who Gets Panretinal Photocoagulation? National Patterns in Proliferative Diabetic Retinopathy Treatment. Ophthalmology Science 2026, 101181. DOI: 10.1016/j.xops.2026.101181.Peer-Reviewed Original ResearchCamrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trial
Peng Z, Zhang Y, Xu H, Yang Y, Yang M, Zhang M, Cheng Y, Chen X, Pan Y, Wang F, Li Q, Xu N, Liu L, Gu K, Xiao J, Zhang R, Zhao Q, Chen J, Lin L, Chen Y, Deng Y, Cai S, Bai B, Wang Y, Shen L. Camrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trial. The BMJ 2026, 392: e086115. PMID: 41819560, PMCID: PMC12980530, DOI: 10.1136/bmj-2025-086115.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsPD-L1-positive populationGastro-oesophageal junction adenocarcinomaHuman epidermal growth factor receptor 2Dose of study drugEpidermal growth factor receptor 2Treatment related adverse eventsPD-L1Junction adenocarcinomaOverall survivalRelated adverse eventsPositive populationOverall populationStudy drugAdverse eventsReceptor 2Eastern Cooperative Oncology Group performance statusAssociated with longer overall survivalProgrammed death-ligand 1Randomised phase 3 trialCombined positive scoreDeath-ligand 1Longer overall survivalPhase 3 trialPeritoneal metastasisTreatment discontinuationValidation of the Ectropion Severity Score in Epidermal Differentiation Disorders
Echeandia-Francis C, Luo A, Jiang X, Ellis K, Mani M, Chen T, Gan G, Deng Y, Choate K. Validation of the Ectropion Severity Score in Epidermal Differentiation Disorders. JAMA Dermatology 2026, 162 PMID: 41779411, PMCID: PMC12961595, DOI: 10.1001/jamadermatol.2025.6166.Peer-Reviewed Original ResearchAltmetricTrastuzumab Rezetecan in Human Epidermal Growth Factor Receptor 2-Expressing Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer: A Multicenter, Open-Label, Phase I Trial.
Liu T, Luo S, Yuan X, Liu D, Zhou Z, Wang X, Deng Y, Chen J, Liu M, Zhou H, Ren X, Qiu W, Cao Y, Cai S, Dong Y, Zhang Y, Wang W, Liang J, Xu P, Liu H, Zhao K, Fan Y, Dou N, Huang C, Li J. Trastuzumab Rezetecan in Human Epidermal Growth Factor Receptor 2-Expressing Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer: A Multicenter, Open-Label, Phase I Trial. Journal Of Clinical Oncology 2026, jco2500716. PMID: 41779980, DOI: 10.1200/jco-25-00716.Peer-Reviewed Original ResearchAltmetricConceptsHuman epidermal growth factor receptor 2Treatment-related adverse eventsProgression-free survivalDose-limiting toxicityGastroesophageal junction adenocarcinomaAntibody-drug conjugatesPhase I trialColorectal cancerMedian OSJunction adenocarcinomaOverall survivalI trialGastric cancerHER2-positive colorectal cancerHER2-targeting antibody-drug conjugateEpidermal growth factor receptor 2Median overall survivalAdvanced gastric cancerDose cohortsOpen-labelStandard treatmentAdverse eventsTrastuzumabReceptor 2PatientsConsensus guidance of immune checkpoint inhibitors in locally advanced rectal cancer
Yang Z, Xia F, Li J, Jin J, Wang G, Lin G, Li X, Wu A, Zhang T, Zhang W, Xu J, Tao K, Ding P, Li Y, Xu Y, Song Z, Li L, Deng Y, Wan X, Xu R, Zhang Z, Yao H, Zhang Z. Consensus guidance of immune checkpoint inhibitors in locally advanced rectal cancer. Gut 2026, gutjnl-2025-336979. PMID: 41748160, DOI: 10.1136/gutjnl-2025-336979.Peer-Reviewed Original ResearchCitationsAltmetricConceptsLocally Advanced Rectal CancerImmune checkpoint inhibitorsTreatment of locally advanced rectal cancerAdvanced rectal cancerConsensus guidanceCheckpoint inhibitorsRectal cancerClinical trialsOrgan preservation treatment strategiesOrgan-sparing strategiesPostoperative adjuvant therapyOrgan preservation strategiesExpert consensus guidanceSociety of Colorectal SurgeryTreatment decision-makingPerioperative immunotherapyPreoperative immunotherapyRadiation therapyAdjuvant therapyLocal resectionColorectal surgeryPerioperative managementFollow-upTreatment strategiesEfficacy evaluationLong‐Term Use of Fenofibrate as Second‐Line Therapy in Primary Biliary Cholangitis: A Retrospective Study
Maxwell M, Deng Y, Chen B, Silveira M, Boyer J, Assis D. Long‐Term Use of Fenofibrate as Second‐Line Therapy in Primary Biliary Cholangitis: A Retrospective Study. Alimentary Pharmacology & Therapeutics 2026 PMID: 41705340, DOI: 10.1111/apt.70574.Peer-Reviewed Original ResearchConceptsPrimary biliary cholangitisSecond-line therapyPrognostic scoreLong-term cohortUrsodeoxycholic acidLong-term useFenofibrate therapyBiliary cholangitisPatients treated with fenofibrateResponse to UDCAEffective second-line treatmentPrimary biliary cholangitis patientsCohort of PBC patientsUK-PBC scoreSecond-line treatmentElevated liver enzymesUrsodeoxycholic acid therapyRetrospective cohort studyPeroxisome proliferator-activated receptor alphaProliferator-activated receptor alphaAlkaline phosphataseFenofibrate useCholestatic markersPBC patientsFIB-4ASO Visual Abstract: Clinical Benefit and Cost-Effectiveness of FOLFOX Versus LCCRT in Neoadjuvant Treatment for Patients With Locally Advanced Rectal Cancer: An Economic Analysis of the FOWARC and PROSPECT Trials
Zhang T, Shi L, Jian L, Jiang J, Qiu Y, Xie F, Zhang J, Peng H, Zhong L, Chen Y, Zhong Y, Deng Y. ASO Visual Abstract: Clinical Benefit and Cost-Effectiveness of FOLFOX Versus LCCRT in Neoadjuvant Treatment for Patients With Locally Advanced Rectal Cancer: An Economic Analysis of the FOWARC and PROSPECT Trials. Annals Of Surgical Oncology 2026, 1-2. PMID: 41688834, DOI: 10.1245/s10434-025-19038-2.Peer-Reviewed Original ResearchClinical Pharmacists, Medications, and Contingency Management for Targeting Smoking in HIV Clinics
Edelman E, Deng Y, Dziura J, Nahum-Shani I, Weiss J, Aoun-Barakat L, Bold K, Harsono D, Mistler C, Payne E, Aiudi S, Sigel K, Yager J, Ledgerwood D, Bernstein S. Clinical Pharmacists, Medications, and Contingency Management for Targeting Smoking in HIV Clinics. JAMA Network Open 2026, 9: e2560593. PMID: 41758512, PMCID: PMC12949440, DOI: 10.1001/jamanetworkopen.2025.60593.Peer-Reviewed Original ResearchThis study investigates clinical pharmacist-led nicotine replacement therapy (NRT) with contingency management (CM) for reducing smoking in people with HIV, showing CM significantly improved abstinence at 12 weeks and reduced smoking when added after NRT nonresponse.Cathepsin-D-mediated MHC class I degradation contributes to immune evasion in colorectal cancer
Zhan W, Fu Y, Liu Y, Cai R, Bai F, Guo C, Cheng Y, Wu Z, Qin G, Xie Y, Zhang J, Deng Y. Cathepsin-D-mediated MHC class I degradation contributes to immune evasion in colorectal cancer. Cell Reports Medicine 2026, 7: 102534. PMID: 41483803, PMCID: PMC12866090, DOI: 10.1016/j.xcrm.2025.102534.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsAnti-PD-1Programmed death-1Major histocompatibility complexColorectal cancerMSS colorectal cancerImmune evasionCytotoxic T cell-mediated killingAnti-PD-1 efficacyAnti-PD-1 immunotherapyT cell-mediated killingPharmacological inhibitionResistance to immunotherapyCathepsin DAntibody monotherapyDeath-1Immunotherapy resistanceCombination therapyImmune escapeTumor cellsGenetic deletionImmunotherapyClass IHistocompatibility complexLight chainCancer
2025
Clinical Benefit and Cost-Effectiveness of FOLFOX Versus LCCRT in Neoadjuvant Treatment for Patients with Locally Advanced Rectal Cancer: An Economic Analysis of the FOWARC and PROSPECT Trial
Zhang T, Shi L, Jian L, Jiang J, Qiu Y, Xie F, Zhang J, Peng H, Zhong L, Chen Y, Zhong Y, Deng Y. Clinical Benefit and Cost-Effectiveness of FOLFOX Versus LCCRT in Neoadjuvant Treatment for Patients with Locally Advanced Rectal Cancer: An Economic Analysis of the FOWARC and PROSPECT Trial. Annals Of Surgical Oncology 2025, 1-13. PMID: 41379261, DOI: 10.1245/s10434-025-18802-8.Peer-Reviewed Original ResearchAltmetricConceptsLocally Advanced Rectal CancerLong-course chemoradiotherapyHigh-risk patientsQuality-adjusted life yearsAdvanced rectal cancerNeoadjuvant treatmentPatient-reported outcomesHealth outcomesProspective trialsRectal cancerNeoadjuvant treatment of locally advanced rectal cancerTreatment of locally advanced rectal cancerOutcomes of adverse eventsYear Follow-UpSocial life impactsFOLFOX groupSupplementary radiotherapyClinical benefitFOLFOXTreatment paradigmHealth utilityAdverse eventsFollow-upHealthcare resourcesCost-effective
News
Copy Link
News
- March 02, 2026
Integrating Tobacco Treatment in HIV Care
- May 29, 2024
Renalase May Predict Post-ERCP Pancreatitis
- January 11, 2023
Discoveries & Impact (January 2023)
- June 15, 2021
Pneumocystis Pneumonia Outbreak Chronicled In Clinical Infectious Diseases
Get In Touch
Copy Link
Contacts
Locations
300 George Street
Academic Office
Ste Suite 555
New Haven, CT 06511